The nociceptin/orphanin FQ (N/OFQ) receptor (NOP) ligands are drug candidates for different diseases, but peptide ligands are often limited by rapid enzymatic degradation and short in vivo duration of action. Here, we applied a multiple D-amino acid substitution strategy to the peptide template [Arg14 Lys15]N/OFQ(1-15)-NH2 to improve metabolic stability while preserving receptor activity. Progressive substitutions revealed marked positional tolerance within the C-terminal address domain and identified [d-Lys13,15d-Arg14]N/OFQ(1–15)-NH2 (compound 1c) as the most promising compound. This led to the Cha1-containing analogue 3a, which retained full agonist efficacy and high selectivity at the NOP receptor in vitro and ex vivo. In vivo, compound 3a induced a long-lasting loss of the righting reflex in mice, closely overlapping the pharmacological profile of the potent and long-acting agonist UFP-112. These findings define the stereochemical tolerance of the NOP receptor toward multiple d-amino acid substitutions within the N/OFQ peptide and demonstrate that this information can be exploited as a rational design strategy to generate NOP receptor agonists with prolonged in vivo activity.

Design of New Potent, Selective, and Long-Acting NOP Receptor Agonists through Multiple Sequential d-Amino Acid Substitutions of [Arg14 Lys15]N/OFQ(1-15)-NH2

Sturaro, Chiara
Primo
;
Rizzo, Alessandra
Secondo
;
Marzola, Erika;Pola, Pietro;Frezza, Alessia;Argentieri, Michela;Agosta, Federica;Ciancetta, Antonella;Preti, Delia;Pacifico, Salvatore;Albanese, Valentina;Meneguzzo, Giulio;Ruzza, Chiara
;
Guerrini, Remo
Ultimo
2026

Abstract

The nociceptin/orphanin FQ (N/OFQ) receptor (NOP) ligands are drug candidates for different diseases, but peptide ligands are often limited by rapid enzymatic degradation and short in vivo duration of action. Here, we applied a multiple D-amino acid substitution strategy to the peptide template [Arg14 Lys15]N/OFQ(1-15)-NH2 to improve metabolic stability while preserving receptor activity. Progressive substitutions revealed marked positional tolerance within the C-terminal address domain and identified [d-Lys13,15d-Arg14]N/OFQ(1–15)-NH2 (compound 1c) as the most promising compound. This led to the Cha1-containing analogue 3a, which retained full agonist efficacy and high selectivity at the NOP receptor in vitro and ex vivo. In vivo, compound 3a induced a long-lasting loss of the righting reflex in mice, closely overlapping the pharmacological profile of the potent and long-acting agonist UFP-112. These findings define the stereochemical tolerance of the NOP receptor toward multiple d-amino acid substitutions within the N/OFQ peptide and demonstrate that this information can be exploited as a rational design strategy to generate NOP receptor agonists with prolonged in vivo activity.
2026
Sturaro, Chiara; Rizzo, Alessandra; Morrone, Erika; Marzola, Erika; Pola, Pietro; Frezza, Alessia; Argentieri, Michela; Agosta, Federica; Ciancetta, A...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2638670
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact